Psychomotor agitation
Drug research and approvals for psychomotor agitation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 48 studies of psychomotor agitation are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 48
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Lactium Premedication to Prevent Emergence AgitationNCT07894484 · Phase 3 · Tanta University · starts Nov 4, 2026
- Comparing the Efficacy of Propofol and Dexmedetomidine in Prevention of Emergence Agitation After Sevoflurane…NCT07799311 · Phase 4 · Pakistan Institute of Medical Sciences · starts Aug 28, 2026
- Protocolized Receptive Music Intervention to Reduce Care Refusal in Nursing Home Residents With Major Neurocognitive…NCT07730957 · Not applicable · LNA SANTE · starts Oct 30, 2025
- PARO-agitation-studyNCT07568093 · Not applicable · Hannover Medical School · starts Dec 15, 2025
- Intranasal Dexmedetomidine vs Oral Midazolam for Premedication in Pediatric SurgeryNCT07565116 · Not applicable · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · starts May 5, 2026
- Therapeutic Cuddling in Critically Ill ChildrenNCT07562048 · Not applicable · University of Calgary · starts Dec 8, 2025
- Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing…NCT07557576 · Not applicable · Iva Smiljanić · starts May 16, 2024
- Effect of Daily Screen Time on Postoperative Emergence Delirium in Children Aged 2-11 YearsNCT07552896 · Not reported · Kanuni Sultan Suleyman Training and Research Hospital · starts May 1, 2026
- Sublingual Caffeine on Reducing Recovery Time and Postoperative Agitation in Elderly Patients Undergoing General…NCT07536568 · Not applicable · Cairo University · starts Apr 18, 2026
Approved 4
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- LoxapineSerotonin 2a (5-HT2a) receptor antagonist
- DiazepamGABA-A receptor; anion channel positive allosteric modulator
- AripiprazoleDopamine D2 receptor partial agonist
Phase 3 9
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- HaloperidolSerotonin 2a (5-HT2a) receptor antagonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- BrexpiprazoleDopamine D2 receptor partial agonist
- CitalopramSerotonin transporter inhibitor
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- PerphenazineDopamine D2 receptor antagonist
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- OxcarbazepineSodium channel alpha subunit blocker
Phase 2 3
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- LevosulpirideDopamine D2 receptor antagonist
- BNC-210Neuronal acetylcholine receptor protein alpha-7 subunit negative allosteric modulator
Phase 1 or earlier 2
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- Fospropofol
How its trials ended
487 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 133 whose ending is known, 58% met their primary endpoint, 5% missed it and 38% stopped early.
- Completed, result not reported22747%
- Met its primary endpoint7716%
- Ongoing6413%
- Status unknown6313%
- Stopped: other or unclear245%
- Stopped: enrollment or feasibility143%
- Missed its primary endpoint61%
- Stopped: lack of efficacy61%
- Stopped: sponsor or business decision61%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA